TCT 2020 | Our Next Goal Should Be Using IVUS Guidance in Every Angioplasty

The benefits of intravascular ultrasound (IVUS) guidance in all angioplasties with second-generation drug-eluting stents (DES) persist through 3 years of follow-up. These data derive from the extended follow-up of the ULTIMATE study, presented virtually at TCT 2020 and published simultaneously in JACC Intv.

TCT 2020 | Guiar con IVUS todas las angioplastias debería ser nuestro próximo objetivo

At 3 years, target-vessel failure remained lower in patients whose angioplasty was guided by IVUS versus unguided angiography (6.6% vs. 10.7%; p = 0.01). This difference was mainly driven by a significant reduction in clinically-driven revascularization (4.5% vs. 6.9%; p = 0.05).

The advantage provided by IVUS guidance was even better when criteria for an optimal procedural result were met (plaque volume <50%, successful expansion, and lack of dissections).

Both the ULTIMATE and the IVUS-XPL (presented at TCT 2019 and also published in JACC Intv.) studies confirm the clinical benefits of IVUS-guided DES angioplasty.


Read also: TCT 2020 | TAVR Appears to Be the Solution for All Dysfunctional Biological Valves.


The ULTIMATE study, conducted at 8 Chinese sites, enrolled 1448 patients who had silent ischemia, stable or unstable angina, or acute infarction (the latter with over 24 hours between index chest pain and procedure). Of all patients, 78.5% presented acute coronary syndrome, 54.9% presented multivessel lesion, and 30.6% had diabetes. Patients in the IVUS arm received, on average, larger-diameter stents and much more frequently post-dilation with non-compliant balloons of larger diameter and at higher atmospheres.

Criteria for an optimal result were: minimum lumen area of the stent segment >5.0 mm2 or 90% of the minimum lumen area at the distal reference segments; plaque burden at 5 mm proximal or distal to stent edge <50%, and no edge dissection involving media with a length >3 mm.

The safety endpoint was definite or probable stent thrombosis, which was observed in 1 patient in the IVUS arm vs. 8 patients in the angiography arm (0.1% vs. 1.1%; p = 0.02).


Read also: TCT 2020 | Initial Studies Show Incredible Results with Lithotripsy in Calcified Lesions.


This research shows that IVUS guidance can improve angioplasty, reducing the need for repeat revascularization and stent thrombosis events.

Original title: Three-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation.

Reference: Xiao-Fei Gao et al. JACC: Cardiovascular Interventions, article in press. DOI: 10.1016/j.jcin.2020.10.001 y presentado simultáneamente en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...